Form 4: Axogen Director Amy McBride Wendell Reports Acquisition of Shares and Stock Options

Amy McBride Wendell, a director at Axogen, Inc., reported the acquisition of common stock and stock options as part of her annual equity grant.

Summary

• On June 6, 2024, Amy McBride Wendell, a director of Axogen, Inc., acquired 10,653 shares of common stock.
• These shares were obtained through restricted stock units.
• Wendell also acquired 18,248 stock options with an exercise price of $7.04.
• These options are part of her annual equity grant for service as a Director.
• The stock options vest on June 6, 2025, and expire on June 6, 2034.
• Following these transactions, Wendell beneficially owns 90,995 shares of common stock and 18,248 stock options.

Sentiment

Score: 7

Explanation: The document reflects a routine insider transaction related to director compensation, which is generally neutral to positive as it aligns director interests with the company's performance.

Positives

• The acquisition of shares and stock options reflects continued alignment of the director's interests with the company's performance.
• The equity grant serves as an incentive for continued service as a Director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

This filing is a routine disclosure of insider transactions, common in publicly traded companies to ensure transparency and compliance with SEC regulations. It reflects standard compensation practices for board members.

Comparison to Industry Standards

• Equity grants to board members are a common practice in publicly traded companies, including those in the biotechnology and medical device sectors.
• The valuation of $150,000 for the annual equity grant appears to be within the typical range for companies of Axogen's size and stage.
• Comparable companies such as Integra LifeSciences and Stryker often provide similar equity-based compensation to their directors.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's long-term success.
• The equity grant serves as an incentive for the director to continue contributing to the company's growth.

Key Dates